Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Characteristic muscle signatures assessed by quantitative MRI in patients with Bethlem myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Physical activity in myotonic dystrophy type 1

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. High-intensity training in patients with spinal and bulbar muscular atrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Functional-structural assessment of the optic pathways in patients with optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Klinisk Neurologi og Neurokirurgi

    Publikation: Bog/antologi/afhandling/rapportBogUndervisning

Vis graf over relationer

Background: Patients with multiple sclerosis who experience disease breakthrough often switch disease-modifying therapy (DMT). Objective: To compare treatment effectiveness of switch to highly effective DMT (heDMT) with switch to moderately effective DMT (meDMT) for patients who switch due to disease breakthrough defined as at least one relapse within 12 months of their treatment switch. Methods: We retrieved data from The Danish Multiple Sclerosis Registry on all relapsing-remitting MS patients with expanded disability status scale (EDSS) less than 6 who experienced disease breakthrough. We used propensity score matching to compare annualized relapse rates (ARRs), time to first confirmed relapse, time to first confirmed EDSS worsening and time to first confirmed EDSS improvement. Results: Each matched group comprised 404 patients. Median follow-up time was 3.2 years [interquartile range (IQR) 1.7–5.8]. ARRs were 0.22 (0.19–0.27) with heDMT and 0.32 (IQR 0.28–0.37) with meDMT; relapse rate ratio was 0.70 (95% CI 0.56–0.86; p = 0.001). Escalation to heDMT reduced the hazard of reaching a first relapse (HR 0.65; 95% CI 0.53–0.80; p < 0.001). We found no evidence of delayed disability worsening (HR 0.83; 95% CI 0.62–1.10; p = 0.20) and weak evidence of disability improvement (HR 1.33; 95% CI 1.00–1.76; p = 0.05) with heDMT. Conclusion: Switching to heDMT is associated with reduced ARR and delay of first relapse compared with switching to meDMT. Patients on DMT who experience relapses should escalate therapy to heDMT.

OriginalsprogEngelsk
TidsskriftJournal of Neurology
Vol/bind266
Udgave nummer2
Sider (fra-til)306-315
Antal sider10
ISSN0340-5354
DOI
StatusUdgivet - 1 feb. 2019

ID: 56665638